Kevin O’Connor, Ph.D., partner at Neal, Gerber & Eisenberg LLP, has expertise in patent law, with a focus on IP due diligence during mergers and acquisitions, collaboration and licensing agreements, as well as patent prosecution and portfolio management. O’Connor holds a Ph.D. in neuroscience and has technical knowledge when it comes to representing global biopharmaceutical companies involving pre-clinical and clinical molecules and other molecular technologies.
Legal 500 Editorial commentary
- Profile
Accolades
Chicago Elite
Key clients
- BioNTech
Work highlights
Leads the team that manages several of BioNTech's US patent assets covering its clinical-stage vaccine technology and antibody therapeutics, including bispecific antibodies and antibody-drug conjugates. The team has obtained several patents in the US protecting BioNTech's technology for oncology and viral indications.